PEOPLE - Helicos BioSciences makes appointment:
This article was originally published in Clinica
Lifescience company Helicos BioSciences (Cambridge, Massachusetts) has announced interim appointments in response to the resignation of Louise Mawhinney, senior vice-president and CFO. President and COO Steve Lombardi will step in as principal financial officer, while Kevin Lafond, the firm's controller, will stand in as principal accounting officer. Ms Mawhinney has left the firm to pursue other interests. Helicos' proprietary genetic analysis technology is designed to be used across the diagnostics, research and drug discovery markets.
You may also be interested in...
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.